1,1'-Disubstituted Ferrocenes as Molecular Hinges in Mono- and Bivalent Dopamine Receptor Ligands

Daniela Huber, Harald Hubner, and Peter Gmeiner*

Department of Chemistry and Pharmacy, Emil Fischer Center, Friedrich Alexander University, Schuhstrasse 19, 91052 Erlangen, Germany

Received July 28, 2009

On the basis of previous work on dopaminergic partial agonists of type **1** and **2**, disubstituted ferrocenes are presented as valuable arene bioisosteres. Because substituents at the distal cyclopentadienyl ring are able to adjust the relative disposition that is required for ligand binding, disubstituted ferrocenes can act as molecular hinges. Taking advantage of click chemistry, the regioselective construction and functionalization of the target molecules is reported. Thus triazole derived appendages were used for the finetuning of biological activity and for the attachment of linker units generating bivalent GPCR ligands. Receptor binding was evaluated by radioligand displacement experiments, revealing superaffinity with sub- to single-digit nanomolar K_i values for particular test compounds. As a neutral antagonist at the dopamine receptors D3 and D4 and a potent partial agonist at the D2 subtype (intrinsic activity = 57%, $EC_{50} = 2.5$ nM), the bifunctional ferrocene **10b** revealed a novel and unique activity profile.

Introduction

Bioisosteric replacement is an efficient concept for lead optimization, significantly extending the chemical space of bioactive ligands.¹ Evaluating atypical bioactive arene surrogates, metallocene-based compounds were reported, including the novel chemotherapeutic agent ferroquine.^{2,3} Starting from dopamine D3 receptor selective lead structures of type **1** and heterocyclic analogues thereof,^{4,5} we have recently shown that metallocene-derived benzamide bioisosteres of type **2** can serve as highly potent G-protein coupled receptor (GPCR^{*a*}) ligands preferentially interacting with the subtypes of the dopamine D2 receptor family, the serotonergic 5-HT_{1A} and the adrenergic α_1 receptor (Chart 1).⁶

The biological activity of benzamides of type 1 can be tuned by the introduction of substituents into ortho-, meta-, and para-positions of the aromatic system.⁷⁻¹⁰ As an extension of our studies on GPCR ligands of type 2, we envisaged to discover the ferrocene derived bifunctional analogues 3. According to earlier studies of arene carboxamides, we anticipated a putative control of subtype selectivity by a careful selection of the spacer that links the ferrocene moiety and the phenylpiperazine substructure.^{11,12} Thus, linker units of type A, B, and C should be employed. Bioisosteric displacement of the arene moiety and beneficial substituents of the lead compound 1 by a conformational flexible, 1,1'-disubstituted ferrocenyl subunit should lead to novel mono- and bivalent scaffolds when the substituents at the distal cyclopentadienyl rings should be able to adopt the relative disposition that is required for ligand binding and thus act as molecular hinges (Chart 2). The enhanced conformational flexibility of the ferrocene derivatives could accelerate lead optimization.





Taking advantage of click chemistry, we herein report on the construction of disubstituted ferrocenes when triazole derived appendages were used as affinity generating groups and for the attachment of linker units generating monovalent and the corresponding bivalent GPCR ligands (Chart 2).^{13–15} Receptor binding was evaluated by radioligand displacement experiments, revealing superaffinity with subnanomolar K_i values for some of the ferrocene derived test compounds. Finally, intrinsic activity was investigated in vitro.

Results and Discussion

Chemical Synthesis. Our initial investigations were directed to the elaboration of a practical synthesis of the

^{*}To whom correspondence should be addressed. Phone: +49913185-29383. Fax: +49 9131 85-22585. E-mail: peter.gmeiner@medchem. uni-erlangen.de.

^{*a*} Abbreviations: GPCR, G-protein coupled receptor; CHO, Chinese hamster ovary; HR-EIMS, high resolution electron ionization mass spectrometry; EI-MS, electron ionization mass spectrometry, APCI-MS, atmospheric pressure chemical ionization mass spectrometry, ESI-MS, electrospray ionization mass spectrometry.

Chart 2. Conformational Flexibility of the Ferrocene Moiety Can Be Exploited to Efficiently Generate Monovalent and Bivalent GPCR Ligands



1'-ethynylferrocene-1-carboxylic acid 7, which should serve as a key intermediate for the synthesis of bioactive carboxamides of type 3. On the basis of a recently described preparation of 1'-ethynylferrocene-1-carbaldehyde,¹⁶ we intended to work out a reaction sequence involving Friedel-Crafts acylation followed by a Vilsmeier type formylation and a final elimination step. In detail, methyl ferrocene carboxylate $(4)^{17}$ was reacted with acetyl chloride in the presence of aluminum chloride to afford the acylation product 5 almost quantitatively (Scheme 1). Subsequent activation of DMF with phosphorus oxychloride and treatment of the resulting Vilsmeier reagent with the ferrocene 5 led to formation of the chloroacrolein derivative 6. Elimination was initiated by subsequent heating in dioxane and sodium hydroxide, leading to the bifunctional ethynylferrocene 7 in 57% overall vield.

The orthogonal reactivity of the ferrocene derived building block 7 was used for a selective functionalization. Upon activation with TBTU and addition of the aminopropyl and aminobutyl substituted phenylpiperazines 8a and 8b,⁹ respectively, the carboxamides 9a,b could be prepared when complete conversion was observed (Scheme 2). Choosing 1,2,3-triazole derivatives as affinity generating appendages, the advantages of click chemistry should be exploited. Following slightly modified recently described protocols for the CuSO₄/sodium ascorbate promoted variant of copper(I)catalyzed azide-alkyne cycloaddition (CuAAC),18 benzylazide¹⁹ as well as pentyl- and hexylazide²⁰ were reacted with the ferrocenylethynes 9a,b to give rise to the target compounds 10a-f in excellent yield. According to our computational docking and mutagenesis studies on classical arene carboxamides, the triazole substituent should direct to the entrance of the binding pocket and thus should be in a highly

Scheme 1^a



^{*a*} Reagents and conditions: (a) acetyl chloride, AlCl₃, CH₂Cl₂, 0 °C, 4 h (99%); (b) POCl₃, DMF, 0 °C (15 min) to RT (2 h) (71%); (c) (1) dry dioxane, reflux, 5 min; (2) 0.5 N NaOH, reflux, 25 min (81%).

Scheme 2^a



^{*a*} Reagents and conditions: (a) TBTU, DIPEA, DMF, CH₂Cl₂, **8a,b**, 0 °C to RT, 4 h (96–99%); (b) sodium ascorbate, CuSO₄, H₂O:'BuOH: CH₂Cl₂ 2:1:1, RT, 16 h (72–98%).

Scheme 3^{*a*}



^{*a*} Reagents and conditions: (a) sodium ascorbate, $CuSO_4$, H_2O : ^{*b*}BuOH: CH₂Cl₂ 2:1:1, RT, 16 h (72–94%); (b) 2-methoxyphenylpiperazine, Na(OAc)₃BH, CH₂Cl₂, RT, 16 h (75–99%).

critical region. Further modifications, however, will be done within future studies for the optimization of the respective dimeric ligands when this moiety will determine the linker length and thus will be highly crucial.

Benzyl piperazines and heterocyclic analogues thereof have been described as dopamine D4 receptor antagonists and partial agonists.^{21–23} To approach to metallocene derived analogues, triazolyl substituted ferrocene carbaldehydes should be prepared and coupled to *ortho*methoxyphenyl piperazine via reductive amination. Again, orthogonal functionalization was envisaged renouncing the use of protecting groups. Thus, triazole formation was done by reacting benzyl-, pentyl-, and hexylazide with the ethynyl substituted building block **11** (Scheme 3).¹⁶ The synthetic Scheme 4^a



^{*a*} Reagents and conditions: (a) sodium ascorbate, $CuSO_4$, H_2O : ^{*b*} BuOH: CH_2Cl_2 2:1:1, RT, 16 h (61–99%); (b) 2-methoxyphenylpiperazine, Na(OAc)_3BH, CH_2Cl_2, RT, 16 h (48–84%).

intermediates **12a**-**c** were reductively aminated with *ortho*methoxyphenylpiperazine, resulting in formation of the test compounds **13a**-**c**.

Taking advantage of the high impact and efficiency of click chemistry, copper promoted 1,3-dipolar cycloaddition should be used for the construction of dimeric dopamine receptor ligands that putatively act as bivalent receptor modulators (Scheme 4).²⁴ According to previous investigations on bivalent ligands containing μ -opioid agonist and type 2 cholecystokinin antagonist receptor pharmacophores,²⁵ spacers with 16-18 atoms were chosen in conformationally flexible and rigidized form. For the synthesis of bivalent carboxamides of type 14a-f, the monomeric ethynyl substituted precursors 9a,b were coupled with aliphatic diazides and biphenyl derivatives²⁶ to afford the reaction products 14a-f in good to excellent yield (61-99%). For a preparation of the respective methylene bridged analogues 16a-c, the building block 11 was reacted with the diazides mentioned above. Reductive amination of the thus formed intermediates 15a-c furnished the dimeric final products 16a-c in 48-84% yield.

Receptor Binding. Radioligand binding assays were employed to analyze affinity and selectivity profiles of the monomeric target compounds 10a-f and 13a-c and its dimeric congeners 14a-f and 16a-c. The K_i values of the test compounds were compared to the properties of the lead structure 2 and the reference agent quinpirole,²⁷ which is known to activate D2, D3, and D4 receptors. The binding data were generated by measuring their ability to compete with [³H]spiperone for the cloned human dopamine receptor subtypes D2_{long}, D2_{short},²⁸ D3,²⁹ and D4.4³⁰ stably expressed in Chinese hamster ovary cells (CHO).³¹ D1 receptor affinities were determined utilizing porcine striatal membranes and the D1 selective radioligand [³H]SCH 23390.³¹

The characterization of the test compounds was initiated by investigating the ferrocenylcarboxamides **10b,d,f** incorporating a butylene spacer and thus displaying the highest degree of similarity with the lead compounds of type **1** and **2**. In fact, the binding data depicted in Table 1 clearly indicate that the benzyl, pentyl, and hexyl substituted triazole units significantly extending the volume of the ferrocene moiety are tolerated by the binding sites of the D2 receptor family. Significant radioligand displacement was observed, leading to K_i values in the nanomolar range. Whereas D4 preference was determined for our core structure 2, the substituted derivatives 10b,d,f revealed superaffinity at D3 resulting in K_i values of 0.34, 1.3, and 0.63 nM, respectively. Competition experiments at $D2_{long}$, $D2_{short}$, and D4.4 led to K_i values between 3.7 and 25 nM, indicating only moderately lower target recognition than for D3. Compared to the aminobutyl substituted ferrocenylcarboxamides 10b,d,f, the aminopropyl analogues **10a,c,e** displayed lower affinity toward D2_{long}, D2_{short}, and D3 but comparable D4 binding, resulting in a significant D4 preference. On the other hand, only weak to moderate D1 affinity was observed for all test compounds. Because of the observation that the lead compounds of type 1 reveal serotonergic and adrenergic properties,³² all ferrocene derived test compounds were investigated for their potency to displace [³H]WAY100635, [³H]ketanserin, and [³H]prazosin. Employing porcine α_1 , 5-HT_{1A} and 5-HT₂ receptors, 10b displayed substantial affinity with K_i values in the nanomolar range (α_1 : $K_i = 2.5$ nM, 5-HT_{1A}: $K_i = 14$ nM, 5-HT₂: $K_i = 260$ nM; data for all test compounds, see Supporting Information).

Because benzyl piperazines and heterocyclic analogues thereof have been described as dopamine D4 receptor ligands,^{21–23} significant D4 recognition was expected for the ferrocene derived analogues **13a–c**. Surprisingly, the displacement studies gave disappointing K_i values (82–130 nM) for D4 and weak preference for D2, indicating that a successful bioisosteric replacement was not possible in this case. This might be due to different binding modes of the ferrocene entity depending on the lengths of the spacer units.

Over the past decade, evidence has accumulated to suggest that GPCRs may function as dimers or large oligomers.³³ Very recently, communication between protomers of

Table 1.	Receptor Binding I	Data for the M	Ionomeric Feri	rocene Compou	1ds 2, 10a-	f, and 13a–o	c and the R	eference Q	uinpirole I	Employing l	Porcine D1
Receptor	and the Human Si	ubtypes D2 _{long}	$_{g}$, D2 _{short} , D3,	and D4.4 Recep	tors						

			$K_{\rm i}$ values (nM) \pm SD ^{<i>a</i>}							
				[³ H]spiperone						
			[³ H]SCH 23390							
compd	п	R	D_1	hD2 _{long}	hD2 _{short}	hD3	hD4.4			
2			1900 ± 250	110 ± 10	78 ± 1.5	6.5 ± 0.54^{b}	0.52 ± 0.086^{b}			
10a	2	benzyl	780 ± 300	140 ± 91	170 ± 14	73 ± 36	2.8 ± 0.14			
10b	3	benzyl	370 ± 7.1	3.7 ± 0.21	4.0 ± 0.50	0.34 ± 0.064	5.4 ± 0.071			
10c	2	pentyl	690 ± 200	44 ± 14	100 ± 0	58 ± 23	4.6 ± 0.14			
10d	3	pentyl	1200 ± 210	25 ± 7.8	15 ± 7.4	1.3 ± 0.35	16 ± 5.0			
10e	2	hexyl	510 ± 260	33 ± 8.5	81 ± 0.71	43 ± 21	3.5 ± 0.21			
10f	3	hexyl	240 ± 71	4.7 ± 0.85	4.4 ± 1.1	0.63 ± 0.042	5.4 ± 1.7			
13a		benzyl	260 ± 85	25 ± 12	49 ± 2.8	370 ± 7.1	82 ± 23			
13b		pentyl	250 ± 35	32 ± 5.7	49 ± 9.9	260 ± 57	87 ± 19			
13c		hexyl	360 ± 19^{b}	39 ± 9.9^{b}	70 ± 8.1^{b}	390 ± 110^{b}	130 ± 13^{b}			
quinpirole			72000 ± 0	950 ± 340^{b}	870 ± 0	49 ± 8.6^b	16 ± 4.7^{b}			

^a Derived from two individual experiments each done in triplicate. ^b K_i values \pm SEM derived from 3–6 experiments each done in triplicate

Chart 3. Structure and Mode of a Mono- (Black) and a Bivalent Ligand Binding (Black and Grey)



Table 2.Receptor Binding Data for the Dimeric Ferrocene Compounds 14a-f, 16a-c, and the Benzamide Analogues 17,18 Employing Porcine D1Receptor and the Human Subtypes D2long, D2short, D3, and D4.4 receptors

			$K_{\rm i}$ values (nM) \pm SD ^{<i>a</i>}							
			[³ H]spiperone							
			[³ H]SCH 23390							
compd	n	R	D_1	hD2 _{long}	hD2 _{short}	hD3	hD4.4			
14a	2	bis-CH2-p-biphenyl	100 ± 52	76 ± 62	54 ± 32	22 ± 16	27 ± 6.4			
14b	3	bis-CH ₂ -p-biphenyl	87 ± 19	15 ± 4.2	14 ± 3.5	1.1 ± 0.21	22 ± 6.4			
14c	2	(CH ₂) ₁₀	210 ± 64	45 ± 13	43 ± 17	9.0 ± 2.8	30 ± 0.71			
14d	3	$(CH_2)_{10}$	430 ± 99	54 ± 18	55 ± 15	8.4 ± 2.3	63 ± 25			
14e	2	(CH ₂) ₁₂	130 ± 7.1	64 ± 22	33 ± 21	7.0 ± 4.2	35 ± 13			
14f	3	$(CH_2)_{12}$	1100 ± 0	240 ± 28	170 ± 21	14 ± 7.2	58 ± 1.4			
16a		bis-CH ₂ -p-biphenyl	20000 ± 2100	64 ± 41	48 ± 46	300 ± 92	480 ± 200			
16b		(CH ₂) ₁₀	400 ± 14	65 ± 4.2	33 ± 11	86 ± 13	190 ± 21			
16c		(CH ₂) ₁₂	$2000 \pm 860^{\ b}$	64 ± 30	100 ± 46^{b}	110 ± 70	360 ± 85^{b}			
17	3	· · ·	3400 ± 1300	$15000 \pm 6200^{\ b}$	$10000 \pm 2100^{\ b}$	230 ± 86^{b}	3400 ± 710			
18	3		9500 ± 6400	2000 ± 140	770 ± 200	70 ± 57	850 ± 640			

^a Derived from two individual experiments each done in triplicate. ^b K_i values \pm SEM derived from 3–4 experiments each done in triplicate

dopamine D2 receptors has been proved to modulate GPCR activation.³⁴

In the course of our investigations of bivalent GPCR ligands putatively binding two binding sites of interacting receptor oligomers, we tried to evaluate the scope of our click chemistry based strategy (Chart 3).

Dopamine receptor binding studies of the dimeric ferrocenylcarboxamides 14a-f and its methylene analogues 16a-c clearly revealed significant GPCR recognition with K_i values between 1.1 and 480 nm at the D2-like subtypes (Table 2).

As observed for the monomers, combination of a butylene spacer and a benzyltriazolyl substituent was superior for dopamine receptor binding. Thus, a binding pattern was observed for the dimer **14b**, which closely resembles the affinity profile of the respective monomer **10b** when the

affinities to $D2_{long}$, $D2_{short}$, D3, and D4 proved to be only three- to 4-fold lower. Comparing the excellent binding data of **14b** ($K_i = 15$, 14, 1.1, and 22 nM for $D2_{short}$, $D2_{long}$, D3, and D4, respectively) with those of the meta- and parasubstituted benzamides as reference dimers **17** and **18** (Chart 4) with poor dopamine receptor binding clearly displayed a highly beneficial effect of the ferrocene-based molecular hinge that obviously allows the conformationally restricted bis-methyl-*p*-biphenyl linker to adopt an optimal orientation.

Functional Experiments. Evaluation of the binding data indicating particular high D2, D3, and D4 affinity for test compound **10b** (FAUC 552) suggested further in vitro studies. As a measure of functional activity, ligand efficacy of the ferrocenylcarboxamide **10b** was determined by a mitogenesis assay measuring the rate of $[^{3}H]$ thymidine

Figure 1. Measurement of [³H]thymidine incorporation as an assay for functional activity of the test compound 10b at the dopamine receptor subtypes $D2_{long}$ (A), D3 (B), and D4 (C) in comparison to the effect of the reference quippirole.

Chart 4. Structures of the Reference Dimers 17 and 18

incorporation into growing CHO10001 cells and a CHO dhfr⁻ cell line stably expressing the human $D2_{long}$, D4.2, and D3 receptor, respectively (Figure 1).^{29,35,36}

Interestingly, test compound 10b displayed to act as a partial agonist at D2_{long} with an intrinsic activity of 57% and an EC₅₀ value of 2.6 nM (Figure 1A), which is very similar to the K_i value of the binding experiments (3.7 nM). This effect could be reversed by the neutral antagonist haloperidol in a concentration dependent manner (see Supporting Information). On the other hand, the ferrocene **10b** did not show any ligand efficacy at the D3 subtype. Because the reference compounds of type 1 and 2 are known as D3 partial agonists, the neutral antagonist properties of 10b are obviously due to the steric demand of the benzyltriazolyl substituent (Figure 1B). Measuring the rate of [³H]thymidine incorporation at D4 indicated only a very low effect (< 20%) at high concentration of 10b (Figure 1C). Thus the bifunctional ferrocene 10b revealed a particularly interesting activity profile, with neutral antagonist properties for D3 and D4 behaving as a potent partial agonist at the D2 subtype.

In conclusion, 1,1'-disubstituted ferrocenes can serve as valuable arene bioisosteres when click chemistry allowed a regioselective construction and functionalization as well as the formation of GPCR binding dimers. Receptor recognition was evaluated by radioligand displacement experiments revealing superaffinity with sub- and single-digit nanomolar K_i values for some of the ferrocene derived test compounds. Aiming to better treat schizophrenia in future, the bifunctional ferrocene **10b** revealed a particularly interesting activity profile when neutral antagonist properties for D3 and D4 combined with a potent partial agonist behavior at the D2 subtype (intrinsic activity = 57%, EC₅₀ = 2.5 nM) could potentially lead to an atypical neuroleptic profile.

Experimental Section

Chemistry. Dry solvents and reagents were of commercial quality and were used as purchased. MS were run on a JEOL JMS-GC Mate II spectrometer by EI (70 eV) with solid inlet or a Bruker Esquire 2000 by APC or ES ionization. HR-EIMS were run on a JEOL JMS-GC Mate II using peak-matching (M/ $\Delta M > 5000$). NMR spectra were obtained on a Bruker Avance 360 or a Bruker Avance 600 spectrometer relative to TMS in the solvents indicated (J value in Hz). Melting points were determined with a MEL-TEMP II melting point apparatus (Laboratory Devices, USA) in open capillaries and given uncorrected. IR spectra were performed on a Jasco FT/IR 410 spectrometer. Purification by flash chromatography was performed using Silica Gel 60; TLC analyses were performed using Merck 60 F254 aluminum sheets and analyzed by UV light (254 nm). Analytical HPLC was performed on Agilent 1100 HPLC systems employing a VWL detector. The purity of all test compounds and key intermediates was determined to be >95%. As a column, a ZORBAX ECLIPSE XDB-C8 $(4.6 \text{ mm} \times 150 \text{ mm}, 5 \,\mu\text{m})$ was used. HPLC purity was measured using several elution systems. System A, eluent: methanol/ water/0.1 N formic acid, 10% methanol for 3 min to 100% methanol in 15 min, 100% for 6 min; flow rate, 0.5 mL/min; λ , 254 nm. System B, eluent: methanol/water/0.1 N formic acid, 30% methanol for 1 min to 100% methanol in 11 min, 100% for 4 min; flow rate, 0.5 mL/min; λ , 254 nm. System C, eluent: methanol/water/0.1 N trifluoroacetic acid, 10-100% methanol in 21 min, 100% for 3 min; flow rate, 1.0 mL/min; λ , 254 nm. System D, eluent: acetonitrile/water/0.1 N trifluoroacetic acid, 10% acetonitrile for 2 min to 50% acetonitrile in 13 min to 100% acetonitrile in 9 min, 100% for 1 min; flow rate, 1.0 mL/min; λ , 254 nm.

Methyl 1'-Acetylferrocene-1-carboxylate (5). Acetyl chloride (1.32 mL, 18.5 mmol) was added at 0 °C to a suspension of anhydrous aluminum chloride (2.46 g, 18.5 mmol) in CH₂Cl₂ (12 mL) and stirred for 15 min. The mixture was then added at 0 °C to a solution of methyl ferrocene-1-carboxylate (4, 1.50 g, 6.15 mmol) in CH₂Cl₂ (23 mL) over a period of 15 min upon stirring under nitrogen atmosphere. To prevent light induced degradation, the flask was covered with aluminum foil during the reaction. After 4 h, the reaction mixture was poured into ice water and the resulting precipitate was solubilized by addition of concentrated HCl. The organic layer was separated, and the aqueous layer was extracted with CH₂Cl₂. The combined organic layers were dried (MgSO₄) and evaporated under reduced pressure to give 5 as an orange solid (1.75 g, 99% yield); mp 99-101 °C. IR 1712, 1666, 1465, 1281, 1146, 671 cm⁻ ¹H NMR (600 MHz, CDCl₃) δ 2.38 (s, 3 H), 3.83 (s, 3 H), 4.42 (m, 2 H), 4.51 (m, 2 H), 4.78 (m, 2 H), 4.82 (m, 2 H). ¹³C NMR (150 MHz, CDCl₃) δ 27.53, 51.71, 70.94, 71.59, 72.62, 72.99, 73.45, 80.51, 170.67, 201.23. EI-MS calcd m/z for C₁₄H₁₄FeO₃: 286.1, found 286 (M⁺).

Methyl 1'-(1-Chloro-3-oxoprop-1-enyl)ferrocene-1-carboxylate (6). POCl₃ (1.42 mL, 15.5 mmol) was added dropwise to anhydrous DMF (1.42 mL) at 0 °C. After stirring for 15 min, the resulting Vilsmeier reagent was added to an ice-cold mixture of **5** (1.64 g, 5.73 mmol) and anhydrous DMF (1 mL) over a period of 15 min. The reaction mixture was warmed to room temperature and stirred for 2 h. The Vilsmeier complex was quenched with sodium acetate trihydrate (6.60 g, 48.7 mmol). Saturated aqueous NaHCO₃ was added until the aqueous phase was neutralized. Extraction with CH₂Cl₂, drying (MgSO₄), and evaporation gave the crude product, which was purified by flash chromatography (*n*-hexane:ethylacetate 6:1) to yield **6** as a red oil (1.36 g, 71% yield): IR 1716, 1666, 1601, 1465, 1281, 1138, 833 cm⁻¹. ¹H NMR (360 MHz, CDCl₃) δ 3.79 (s, 3 H), 4.44 (m, 2 H), 4.56 (m, 2 H), 4.75 (m, 2 H), 4.84 (m, 2 H), 6.35 (d, 1 H, *J*=7.04 Hz), 10.10 (d, 1 H, *J*=7.04 Hz). ¹³C NMR: (90 MHz, CDCl₃) δ 51.75, 69.98, 72.45, 73.43, 73.90, 81.55, 121.45, 152.97, 170.20, 190.62. EI-MS calcd *m*/*z* for C₁₅H₁₃ClFeO₃: 332.6, found 332 (M⁺).

1'-Ethynylferrocene-1-carboxylic Acid (7). A solution of 6 (1.36 g, 4.09 mmol) in anhydrous dioxane (26 mL) was heated at reflux temperature for 5 min and subsequently treated with a boiling solution of 0.5 N NaOH (49.2 mL). The reaction mixture was refluxed for 25 min and subsequently cooled by addition of ice water. Neutralization with diluted HCl was followed by extraction with CH₂Cl₂. The organic layer was dried (Na₂SO₄), and the solvent was removed by reduced pressure. The residue was purified by flash chromatography (*n*-hexane:Et₂O 1:1) to give 7 as a red–orange solid (846 mg, 81% yield); mp 144–145 °C. IR 2110, 1674, 1477, 1296, 1165, 1029, 829, 744 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 2.80 (s, 1 H), 4.29 (m, 2 H), 4.45 (m, 2 H), 4.50 (m, 2 H), 4.52 (m, 2 H). ¹³C NMR (150 MHz, CDCl₃) δ 66.41, 70.72, 71.87, 72.11, 73.25, 73.96, 74.92, 80.18, 176.65. HPLC system A (245 nm) purity 96% (t_R = 20.5 min). EI-MS calcd *m*/*z* for C₁₃H₁₀FeO₂: 254.1, found 254 (M⁺).

1'-Ethynyl-N-{3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}ferrocene-1-carboxamide (9a). DIPEA (0.52 mL, 3.2 mmol) was added to a solution of 7 (0.20 g, 0.79 mmol) in anhydrous CH₂Cl₂ (65 mL). The solution was cooled to 0 °C, and subsequently TBTU (0.31 g, 0.97 mmol) in anhydrous DMF (16 mL) was added. After stirring for 15 min, 8a (0.35 g, 1.4 mmol) in anhydrous CH₂Cl₂ (82 mL) was added dropwise. The reaction mixture was warmed to room temperature and stirred for 4 h. The reaction was quenched with saturated aqueous NaHCO₃ and extracted with CH2Cl2. The combined organic layers were dried (Na₂SO₄) and evaporated. The residue was purified by flash chromatography (CH₂Cl₂:MeOH 98:2) to give 9a as an orange solid (0.38 g, 99% yield); mp 156-158 °C. IR 3290, 2939, 2816, 2110, 1635, 1539, 1500, 1454, 1300, 1242, 1030, 749 cm⁻ ¹H NMR (360 MHz, CDCl₃) δ 1.83 (m, 2 H), 2.63 (br t, 2 H, J =6.36 Hz), 2.69–2.84 (m, 5 H), 3.18 (m, 4 H), 3.52 (dt, 2 H, J₁ = 5.98 Hz, J₂=5.98 Hz), 3.87 (s, 3 H), 4.24 (m, 2 H), 4.36 (m, 2 H), 4.45 (m, 2 H), 4.71 (m, 2 H), 6.84–7.07 (m, 4 H), 7.12 (m, 1 H). ¹³C NMR (150 MHz, CDCl₃) δ 25.35, 39.49, 50.54, 53.64, 55.41, 57.68, 65.20, 70.15, 70.52, 72.24, 73.26, 74.62, 78.07, 81.58, 111.29, 118.23, 121.04, 123.15, 141.02, 152.31, 169.28. HPLC system A (245 nm) purity 98% ($t_R = 16.3 \text{ min}$). APCI-MS calcd m/z for C₂₇H₃₁FeN₃O₂: 485.4, found 486 (M + H)⁺

1'-Ethynyl-N-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}ferrocene-1-carboxamide (9b). Compound 9b was prepared according to the protocol of 9a using a solution of 7 (0.20 g, 0.79 mmol) in anhydrous CH₂Cl₂ (65 mL) as well as DIPEA (0.52 mL, 3.2 mmol) and TBTU (0.31 g, 0.97 mmol) in anhydrous DMF (16 mL) and 8b (0.37 g, 1.4 mmol) in anhydrous CH₂Cl₂ (82 mL) to give 9b as a brown oil (0.38 g, 96% yield): IR 3298, 2939, 2819, 2110, 1631, 1539, 1500, 1450, 1300, 1242, 1026, 795, 752 cm^{-1} . ¹H NMR (360 MHz, CDCl₃) δ 1.62–1.76 (m, 4 H), 2.58 (m, 2 H), 2.78 (m, 4 H), 2.82 (s, 1 H), 3.15 (m, 4 H), 3.44 (dt, $2 H, J_1 = 6.28 Hz, J_2 = 6.19 Hz$, 3.86 (s, 3 H), 4.26 (m, 2 H), 4.38(m, 2 H), 4.44 (m, 2 H), 4.65 (m, 2 H), 6.16 (m, 1 H), 6.83-7.05 (m, 4 H). ¹³C NMR (90 MHz, CDCl₃) δ 23.89, 27.69, 39.33, 50.18, 53.43, 55.40, 58.04, 64.98, 70.50, 72.12, 73.48, 74.72, 77.89, 81.75, 111.30, 118.34, 121.06, 123.17, 140.98, 152.30, 169.44. HPLC system A (245 nm) purity 98% ($t_{\rm R} = 16.2 \text{ min}$).

APCI-MS calcd m/z for C₂₈H₃₃FeN₃O₂: 499.4, found 500 (M + H)⁺.

1'-(1-Benzyl-1H-1,2,3-triazole-4-yl)-N-{3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}ferrocene-1-carboxamide (10a). A suspension of 9a (26 mg, 54 µmol), benzyl azide (21 mg, 0.16 mmol), sodium ascorbate (2.2 mg, 11 μ mol), and copper sulfate pentahydrate (0.7 mg, 2.8 µmol) in H₂O (1 mL), ^tBuOH (0.5 mL), and CH₂Cl₂ (0.5 mL) was stirred at room temperature overnight. The reaction was quenched with saturated aqueous NaHCO₃, extracted with CH₂Cl₂, dried (Na₂SO₄), and evaporated. The residue was purified by flash chromatography (CH2Cl2:MeOH 98:2-95:5) to give **10a** as an orange solid (32 mg, 96% yield); mp 102–105 °C. IR 3325, 2939, 2819, 1635, 1539, 1500, 1454, 1300, 1242, 1026, 752 cm⁻¹. ¹H NMR (360 MHz, CDCl₃) δ 1.79 (m, 2 H), 2.59 (brt, 2 H, J=6.58 Hz), 2.74 (m, 4 H), 3.16 (m, 4 H),3.28 (dt, 2 H, $J_1 = 6.13$ Hz, $J_2 = 6.02$ Hz), 3.87 (s, 3 H), 4.25 (m, 2 H), 4.31 (m, 2 H), 4.53 (m, 2 H), 4.60 (m, 2 H), 5.53 (s, 2 H), 6.84-6.90 (m, 1 H), 6.91-6.98 (m, 2 H), 6.99-7.05 (m, 1 H), 7.29-7.44 (m, 5 H), 7.48 (s, 1 H), 7.55 (m, 1 H). ¹³C NMR (90 MHz, CDCl₃) δ 25.42, 39.17, 50.55, 53.57, 54.14, 55.40, 57.45, 68.62, 69.76, 69.98, 70.85, 76.88, 78.75, 111.30, 118.25, 120.07, 121.07, 123.01, 128.11, 128.74, 129.13, 134.70, 141.22, 145.48, 152.34, 169.12. HPLC system D (245 nm) purity > 99% $(t_{\rm R} = 15.8 \text{ min})$. HR-EIMS calcd m/z for C₃₄H₃₈FeN₆O₂: 618.2406, found 618.2408.

1'-(1-Benzyl-1H-1,2,3-triazole-4-yl)-N-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}ferrocene-1-carboxamide (10b). Compound 10b was prepared according to the protocol of 10a using a suspension of 9b (25.5 mg, 51.1 µmol), benzylazide (20.4 mg, 0.153 mmol), sodium ascorbate (2.0 mg, 10.1 µmol), and copper sulfate pentahydrate (0.7 mg, 2.80 μ mol) in H₂O (1 mL), ^tBuOH (0.5 mL), and CH₂Cl₂ (0.5 mL) to give **10b** as an orange solid (27.0 mg, 83% yield); mp 98-101 °C. IR 3317, 2939, 2819, 1635, 1539, 1500, 1454, 1300, 1242, 1026, 752 cm⁻ ¹H NMR: (360 MHz, CDCl₃) δ 1.62–1.76 (m, 4 H), 2.51 (m, 2 H), 2.71 (m, 4 H), 3.12 (m, 4 H), 3.32 (m, 2 H), 3.85 (s, 3 H), 4.26 (m, 2 H), 4.33 (m, 2 H), 4.45 (m, 2 H), 4.54 (m, 2 H), 5.54 (s, 2 H), 6.82–6.87 (m, 1 H), 6.88–6.95 (m, 2 H), 6.96–7.02 (m, 1 H), 7.15 (m, 1 H), 7.28–7.45 (m, 6 H). ¹³C NMR (90 MHz, CDCl₃) & 24.26, 27.66, 39.41, 50.44, 53.41, 54.21, 55.38, 58.27, 69.18, 69.79, 70.44, 70.68, 76.46, 78.77, 111.25, 118.28, 119.99, 121.02, 122.94, 128.09, 128.82, 129.18, 134.59, 141.28, 145.95, 152.30, 169.72. HPLC system D (245 nm) purity 98% ($t_{\rm R} = 15.7$ min). HR-EIMS calcd m/z for C35H40FeN6O2: 632.2562, found 632.2558

N-{**3-[4-(2-Methoxyphenyl)piperazin-1-yl]propyl**}-**1**'-(**1-pentyl-1***H*-**1,2,3-triazole-4-yl)ferrocene-1-carboxamide** (**10c**). Sodium azide (1.73 g, 26.6 mmol) was added to a solution of 1-bromopentane (830 μ L, 6.65 mmol) in CH₃CN (9 mL) and H₂O (1 mL) and heated at reflux temperature overnight. The reaction was quenched with saturated aqueous NaHCO₃, extracted with *n*-hexane, dried (Na₂SO₄), and evaporated to 3.1 mL to obtain a concentration of 1-azidopentane of 2.15 mmol/mL.

Compound 10c was prepared according to the protocol of 10a using a suspension of 9a (26.2 mg, 54.0 μ mol), a 2.15 M solution of 1-azidopentane in n-hexane (75.3 µL, 0.162 mmol), sodium ascorbate (2.10 mg, 10.8 μ mol), and copper sulfate pentahydrate (0.7 mg, 2.80 µmol) in H₂O (1 mL), 'BuOH (0.5 mL), and CH₂Cl₂ (0.5 mL). Purification by flash chromatography (CH₂Cl₂:MeOH 98:2-97:3) gave 10c as an orange solid (24.6 mg, 76% yield); mp 108–111 °C. IR 3309, 2931, 2819, 1635, 1539, 1500, 1450, 1300, 1242, 1026, 748 cm⁻¹. ¹H NMR (360 MHz, CDCl₃) δ 0.92 (t, 3 H, J = 6.93 Hz), 1.30–1.44 (m, 4 H), 1.81 (m, 2 H), 1.94 (m, 2 H), 2.59 (br t, 2 H, J=6.47 Hz),2.73 (m, 4 H), 3.16 (m, 4 H), 3.32 (dt, 2 H, J₁ = 6.21 Hz, J₂ = 6.07 Hz), 3.87 (s, 3 H), 4.26 (m, 2 H), 4.30-4.38 (m, 4 H), 4.53 (m, 2 H), 4.63 (m, 2 H), 6.84-7.05 (m, 4 H), 7.55 (s, 1 H), 7.57 (m, 1 H). ¹³C NMR (90 MHz, CDCl₃) δ 13.87, 22.12, 25.44, 28.68, 29.98, 39.27, 50.36, 50.60, 53.59, 55.40, 57.52, 68.67, 69.69, 70.02, 70.80, 77.24, 78.77, 111.30, 118.23, 119.97, 121.06, 123.00, 141.26, 144.96, 152.35, 169.17. HPLC system A (245 nm) purity 97% ($t_{\rm R}$ = 17.5 min); system D (245 nm) purity >99% ($t_{\rm R}$ = 16.6 min). HR-EIMS calcd m/z for C₃₂H₄₂-FeN₆O₂: 598.2719, found 598.2719.

 $N-\{4-[4-(2-Methoxyphenyl)piperazin-1-yl]butyl\}-1'-(1-pentyl-)$ 1H-1,2,3-triazole-4-yl)ferrocene-1-carboxamide (10d). Compound **10d** was prepared according to the protocol of **10a** using a suspension of 9b (19.5 mg, 39.0 µmol), a 2.15 M solution of 1azidopentane in n-hexane (54.0 µL, 0.117 mmol), sodium ascorbate (1.50 mg, 7.57 μ mol), and copper sulfate pentahydrate (0.5 mg, 1.95 µmol) in H₂O (1 mL), ^tBuOH (0.5 mL) and CH₂Cl₂ (0.5 mL) to give **10d** as a red-orange solid (19.5 mg, 81% yield); mp 82–85 °C. IR 3324, 2934, 2816, 1635, 1540, 1500, 1451, 1297, 1241, 1026, 750 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 0.92 (t, 3 H, J = 6.99 Hz), 1.32–1.42 (m, 4 H), 1.62–1.72 (m, 4 H), 1.95 (m, 2 H), 2.50 (br t, 2 H, J = 6.61 Hz), 2.70 (m, 4 H), 3.12 (m, 4 H), 3.34 (dt, 2 H, $J_1 = 6.04$ Hz, $J_2 = 5.95$ Hz), 3.86 (s, 3 H), 4.28 (m, 2 H), 4.33-4.39 (m, 4 H), 4.45 (m, 2 H), 4.57 (m, 2 H), 6.83-6.88 (m, 1 H), 6.89-6.96 (m, 2 H), 6.97-7.02 (m, 1 H), 7.20 (m, 1 H), 7.51 (s, 1 H). 13 C NMR (150 MHz, CDCl₃) δ 13.88, 22.12, 24.29, 27.66, 28.67, 29.99, 39.42, 50.42, 50.47, 53.41, 55.36, 58.28, 69.20, 69.73, 70.46, 70.64, 76.68, 78.76, 111.20, 118.26, 119.90, 121.00, 122.94, 141.27, 145.38 152.29, 169.76. HPLC system B (245 nm) purity 96% ($t_{\rm R} =$ 8.5 min); system D (245 nm) purity >99% ($t_{\rm R} = 16.4$ min). HR-EIMS calcd m/z for C₃₃H₄₄FeN₆O₂: 612.2875, found 612.2875.

1'-(1-Hexyl-1*H*-1,2,3-triazole-4-yl)-*N*-{3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}ferrocene-1-carboxamide (10e). Sodium azide (793 mg, 12.2 mmol) was added to a solution of 1bromohexane (0.430 mL, 3.05 mmol) in CH₃CN (9 mL) and H₂O (1 mL) and heated at reflux temperature overnight. The reaction was quenched with saturated aqueous NaHCO₃, extracted with *n*-hexane, dried (Na₂SO₄), and evaporated to 7.80 mL to obtain a concentration of 1-azidohexane of 0.391 mmol/mL.

Compound 10e was prepared according to the protocol of 10a using a suspension of 9a (23.1 mg, 47.6 µmol), a 0.391 M solution of 1-azidohexane in n-hexane (366 µL, 0.143 mmol), sodium ascorbate (1.90 mg, 9.60 μ mol), and copper sulfate pentahydrate (0.6 mg, 2.40 µmol) in H₂O (1 mL), ^tBuOH (0.5 mL) and CH₂Cl₂ (0.5 mL) to give 10e as an orange solid (28.6 mg, 98% yield); mp 87-89 °C. IR 3336, 2931, 2819, 1635, 1539, 1500, 1450, 1300, 1242, 1026, 795, 748 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 0.89 (t, 3 H, J = 6.99 Hz), 1.28–1.40 (m, 6 H), 1.81 (m, 2 H), 1.94 (m, 2 H), 2.59 (br t, 2 H, J=6.61 Hz),2.74 (m, 4 H), 3.16 (m, 4 H), 3.32 (dt, 2 H, J₁ = 6.29 Hz, J₂ = 6.14 Hz), 3.87 (s, 3 H), 4.26 (m, 2 H), 4.33 (m, 2 H), 4.35 (t, 2 H, J = 7.37 Hz), 4.53 (m, 2 H), 4.63 (m, 2 H), 6.85–6.89 (m, 1 H), 6.91-6.97 (m, 2 H), 6.99-7.04 (m, 1 H), 7.55 (s, 1 H), 7.60 (m, 1 H). ¹³C NMR (90 MHz, CDCl₃) δ 13.90, 22.39, 25.39, 26.19, 30.21, 31.13, 39.21, 50.34, 50.54, 53.54, 55.36, 57.47, 68.63, 69.65, 69.99, 70.77, 77.08, 78.71, 111.26, 118.19, 119.92, 121.01, 122.96, 141.21, 144.92, 152.30, 169.14. HPLC system C (245 nm) purity 99% ($t_{\rm R}$ = 18.3 min); system D (245 nm) purity >99% ($t_R = 17.8 \text{ min}$). HR-EIMS calcd m/z for C₃₃H₄₄-FeN₆O₂: 612.2875, found 612.2875.

1'-(1-Hexyl-1*H*-1,2,3-triazole-4-yl)-*N*-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}ferrocene-1-carboxamide (10f). Compound 10f was prepared according to the protocol of 10a using a suspension of 9b (25.2 mg, 50.5 μmol), a 0.391 M solution of 1-azidohexane in *n*-hexane (390 μL, 0.152 mmol), sodium ascorbate (2.0 mg, 10.1 μmol), and copper sulfate pentahydrate (0.6 mg, 2.40 μmol) in H₂O (1 mL), 'BuOH (0.5 mL) and CH₂Cl₂ (0.5 mL) to give 10f as an orange solid (23.0 mg, 72% yield); mp 68–72 °C. IR 3317, 2931, 1635, 1539, 1500, 1454, 1300, 1242, 1026, 667 cm⁻¹. ¹H NMR (360 MHz, CDCl₃) δ 0.89 (t, 3 H, J = 7.15 Hz), 1.28–1.45 (m, 6 H), 1.61–1.76 (m, 4 H) 1.94 (m, 2 H), 2.52 (br t, 2 H, J = 7.04 Hz), 2.71 (m, 4 H), 3.14 (m, 4 H), 3.34 (dt, 2 H, $J_1 = 6.28$ Hz, $J_2 = 6.13$ Hz), 3.86 (s, 3 H), 4.27 (m, 2 H), 4.31–4.39 (m, 4 H), 4.46 (m, 2 H), 4.57 (m, 2 H), 6.81–7.03 (m, 4 H), 7.18 (m, 1 H), 7.51 (s, 1 H). ¹³C NMR (90 MHz, CDCl₃) δ 13.94, 22.43, 24.24, 26.22, 27.65, 30.25, 31.16, 39.41, 50.44, 53.41, 55.38, 58.26, 69.19, 69.74, 70.46, 70.66, 78.76, 111.27, 118.28, 119.90, 121.03, 122.95, 141.28, 145.39, 152.31, 169.76. HPLC system A (245 nm) purity 98% ($t_R = 18.0$ min); system D (245 nm) purity > 99% ($t_R = 17.7$ min). HR-EIMS calcd m/z for C₃₄H₄₆-FeN₆O₂: 626.3032, found 626.3038.

1'-(1-Benzyl-1*H*-1,2,3-triazole-4-yl)ferrocene-1-carbaldehyde (12a). A suspension of 1'-ethynylferrocene-1-carbaldehyde (11, 66.4 mg, 0.279 mmol), benzylazide (111 mg, 0.837 mmol), sodium ascorbate (11.1 mg, 56.0 μ mol), and copper sulfate pentahydrate (3.50 mg, 14.0 µmol) in H₂O (4 mL), ^tBuOH (2 mL), and CH₂Cl₂ (2 mL) was stirred at room temperature overnight. Afterward, the reaction was quenched with saturated aqueous NaHCO₃ and extracted with CH₂Cl₂. The combined organic layers were dried (Na₂SO₄), and the solvent was removed under reduced pressure. The residue was purified by flash chromatography (n-hexane:Et₂O 1:1) to give 12a as an orange solid (97.9 mg, 94% yield); mp 128-131 °C. IR 3113, 2924, 1678, 1454, 1246, 1045, 825, 721 cm⁻¹. ¹H NMR (360 MHz, CDCl₃) δ 4.36 (m, 2 H), 4.50 (m, 2 H), 4.66 (m, 2 H), 4.79 (m, 2 H), 5.55 (s, 2 H), 7.28–7.33 (m, 2 H), 7.35–7.45 (m, 4 H), 9.70 (s, 1 H). ¹³C NMR (90 MHz, CDCl₃,) δ 54.19, 68.00, 70.03, 70.96, 74.53, 77.71, 79.97, 119.52, 128.00, 128.77, 129.15, 134.71, 145.10, 193.57. HPLC system A (245 nm) purity 96% ($t_{\rm R}$ = 18.9 min). APCI-MS calcd m/z for C₂₀H₁₇Fe- $N_3O: 371.2$, found 372 $(M + H)^+$.

1'-(1-Pentyl-1*H*-1,2,3-triazole-4-yl)ferrocene-1-carbaldehyde (12b). Compound 12b was prepared according to the protocol of 12a using a suspension of 11 (63.2 mg, 0.265 mmol), a 2.15 M solution of 1-azidopentane in *n*-hexane (372 μ L, 800 μ mol), sodium ascorbate (10.5 mg, 53.0 μ mol), and copper sulfate pentahydrate (3.3 mg, 13.2 µmol) in H₂O (4 mL), ^tBuOH (2 mL), and CH₂Cl₂ (2 mL) to give **12b** as an orange brown solid (87.5 mg, 93% yield); mp 68-70 °C. IR 3498, 3120, 2954, 2931, 1682, 1454, 1246, 1049, 825, 744 cm⁻¹. ¹H NMR (360 MHz, CDCl₃) δ 0.92 (t, 3 H, J = 6.93 Hz), 1.30–1.42 (m, 4 H), 1.95 (m, 2 H), 4.33–4.40 (m, 4 H), 4.53 (m, 2 H), 4.67 (m, 2 H), 4.83 (m, 2 H), 7.47 (s, 1 H), 9.71 (s, 1 H). ¹³C NMR (90 MHz, CDCl₃) δ 13.87, 22.10, 28.63, 29.95, 50.40, 68.02, 69.97, 71.00, 74.48, 77.99, 80.00, 119.42, 144.48, 193.57. HPLC system A (245 nm) purity 99% ($t_{\rm R} = 19.7$ min). APCI-MS calcd m/z for C₁₈H₂₁FeN₃O: 351.2, found 352 $(M + H)^{+}$

1'-(1-Hexyl-1*H*-1,2,3-triazole-4-yl)ferrocene-1-carbaldehyde (12c). Compound 12c was prepared according to the protocol of 12a using a suspension of 11 (34.5 mg, 145 μmol), a 0.391 M solution of 1-azidohexane in *n*-hexane (111 μL, 0.435 mmol), sodium ascorbate (5.80 mg, 29.3 μmol), and copper sulfate pentahydrate (1.8 mg, 7.21 μmol) in H₂O (2 mL), 'BuOH (1 mL), and CH₂Cl₂ (1 mL) to give 12c as an orange-brown solid (38.3 mg, 72% yield); mp 79-80 °C. IR 3118, 2927, 2856, 1682, 1456, 1244, 1047, 822, 742 cm⁻¹. ¹H NMR (360 MHz, CDCl₃) δ 0.89 (t, 3 H, *J* = 7.04 Hz), 1.27-1.41 (m, 6 H), 1.95 (m, 2 H), 4.33-4.40 (m, 4 H), 4.53 (m, 2 H), 4.67 (m, 2 H), 4.83 (m, 2 H), 7.46 (s, 1 H), 9.71 (s, 1 H). ¹³C NMR (150 MHz, CDCl₃), δ 13.96, 22.45, 26.18, 30.24, 31.18, 50.42, 68.03, 69.99, 71.02, 74.50, 77.96, 79.98, 119.42, 144.49, 193.63. HPLC system A (245 nm) purity 99% (t_R = 20.5 min). APCI-MS calcd *m*/*z* for C₁₉H₂₃FeN₃O: 365.3 found 366 (M + H)⁺.

1-{[1'-(1-Benzyl-1*H***-1,2,3-triazole-4-yl)ferrocene-1-yl]methyl}-4-(2-methoxyphenyl)piperazine (13a).** A solution of **12a** (21.1 mg, 56.8 μ mol), 1-(2-methoxyphenyl)piperazine (16.4 mg, 85.2 μ mol), and Na(OAc)_3BH (25.3 mg, 114 μ mol) in anhydrous CH₂Cl₂ (13 mL) was stirred at room temperature overnight. The reaction mixture was quenched with saturated aqueous NaH-CO₃ and extracted with CH₂Cl₂. The combined organic layers were dried (Na₂SO₄) and evaporated. The residue was purified by flash chromatography (CH₂Cl₂:MeOH 98:2) to give **13a** as a yellow–orange solid (27.3 mg, 87% yield); mp 121–125 °C. IR 2939, 2816, 1500, 1454, 1238, 1026, 752 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 2.50 (m, 4 H), 3.01 (m, 4 H), 3.16 (s, 2 H), 3.84 (s, 3 H), 4.03 (m, 2 H), 4.07 (m, 2 H), 4.25 (m, 2 H), 4.65 (m, 2 H), 5.54 (s, 2 H), 6.81–6.85 (m, 1 H), 6.86–6.91 (m, 2 H), 6.94–7.00 (m, 1 H), 7.28–7.32 (m, 2 H), 7.34–7.42 (m, 4 H). ¹³C NMR (150 MHz, CDCl₃) δ 50.39, 52.70, 54.10, 55.33, 57.59, 66.98, 69.17, 69.65, 71.79, 75.75, 82.97, 111.15, 118.21, 118.66, 120.97, 122.83, 127.96, 128.71, 129.16, 134.93, 141.35, 146.73, 152.24. HPLC system A (245 nm) purity 98% (t_R = 16.5 min); system D (245 nm) purity > 99% (t_R = 16.7 min). HR-EIMS calcd *m*/*z* for C₃₁H₃₃FeN₅O: 547.2035, found 547.2035.

1-(2-Methoxyphenyl)-4-{[1'-(1-pentyl-1H-1,2,3-triazole-4yl)ferrocene-1-yl]methyl}piperazine (13b). Compound 13b was prepared according to the protocol of 13a using a solution of 12b $(20.4 \text{ mg}, 58.1 \,\mu\text{mol}), 1-(2-\text{methoxyphenyl})$ piperazine (16.8 mg, 87.2 μmol), and Na(OAc)₃BH (25.7 mg, 116 μmol) in CH₂Cl₂ (13 mL) to give 13b as an orange-brown solid (30.4 mg, 99%) yield); mp 92–94 °C. IR 2931, 2816, 1500, 1454, 1238, 1025, 748 cm⁻¹. ¹H NMR (600 MHz, CDCl₃,) δ 0.92 (t, 3 H, J = 6.99 Hz), 1.30-1.43 (m, 4 H), 1.94 (m, 2 H), 2.55 (m, 4 H), 3.02 (m, 4 H), 3.23 (s, 2 H), 3.83 (s, 3 H), 4.05 (m, 2 H), 4.10 (m, 2 H), 4.27 (m, 2 H), 4.35 (t, 2 H, J=7.18 Hz), 4.68 (m, 2 H), 6.81-6.84 (m, 1 H), 6.86–6.90 (m, 2 H), 6.94–6.99 (m, 1 H), 7.44 (s, 1 H). ¹³C NMR (150 MHz, CDCl₃,) δ 13.90, 22.12, 28.66, 30.08, 50.29, 50.38, 52.74, 55.32, 57.65, 66.98, 69.14, 69.69, 71.80, 76.01, 82.97, 111.14, 118.21, 118.58, 120.96, 122.84, 141.32, 146.10, 152.24. HPLC system A (245 nm) purity 97% ($t_R = 16.9 \text{ min}$); system D (245 nm) purity >99% ($t_R = 17.5 \text{ min}$). HR-EIMS calcd m/z for C₂₉H₃₇FeN₅O: 527.2348, found 527.2348.

1-{[1'-(1-Hexyl-1H-1,2,3-triazole-4-yl)ferrocene-1-yl]methyl}-4-(2methoxyphenyl)piperazine (13c). Compound 13c was prepared according to the protocol of 13a using a solution of 12c (29.2 mg, 80.0 µmol), 1-(2-methoxyphenyl)piperazine (23.1 mg, 120 µmol), and Na(OAc)₃BH (35.5 mg, 160 µmol) in CH₂Cl₂ (19 mL). Purification by flash chromatography (CH₂Cl₂:MeOH 98:2-95:5) gave 13c as a yellow-orange solid (32.7 mg, 75%) yield); mp 91-93 °C. IR 2931, 2816, 1500, 1454, 1238, 1026, 748 cm⁻¹. ¹H NMR (360 MHz, CDCl₃) δ 0.89 (t, 3 H, J = 7.15 Hz), 1.21-1.42 (m, 6 H), 1.93 (m, 2 H), 2.56 (m, 4 H), 3.02 (m, 4 H), 3.24 (s, 2 H), 3.83 (s, 3 H), 4.05 (m, 2 H), 4.10 (m, 2 H), 4.27 (m, 2 H), 4.35 (t, 2 H, J=7.27 Hz), 4.68 (m, 2 H), 6.80-6.84 (m, 1 H), 6.86-6.90 (m, 2 H), 6.92-7.00 (m, 1 H), 7.44 (s, 1 H). ¹³C NMR (150 MHz, CDCl₃) δ 13.96, 22.45, 26.20, 30.34, 31.17, 50.30, 50.35, 52.70, 55.32, 57.62, 66.98, 69.14, 69.72, 71.80, 76.00, 82.82, 111.13, 118.21, 118.58, 120.96, 122.86, 141.29, 146.09, 152.23. HPLC system A (245 nm) purity 99% $(t_{\rm R} = 18.0 \text{ min})$; system D (245 nm) purity > 99% ($t_{\rm R} = 18.7 \text{ min}$). HR-EIMS calcd m/z for C₃₀H₃₉FeN₅O: 541.2504, found 541.2505.

1',1"-[Biphenyl-4,4'-diylbis(methylene-1H-1,2,3-triazole-1,4diyl)]bis(N-{3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}ferrocene-1-carboxamide) (14a). A suspension of 9a (36 mg, 75 µmol), 4,4'-bis(azidomethyl)biphenyl (6.7 mg, 25 µmol), sodium ascorbate (1.0 mg, 5.0 µmol), and copper sulfate pentahydrate (0.3 mg, 1.2 µmol) in H₂O (2 mL), ^tBuOH (1 mL), and CH₂Cl₂ (1 mL) was stirred at room temperature overnight. The reaction was quenched with saturated aqueous NaHCO₃, extracted with CH₂Cl₂, dried (Na₂SO₄), and evaporated. The residue was purified by flash chromatography (CH₂Cl₂:MeOH 95:5-9:1) to give 14a as an orange solid (27 mg, 88% yield); mp 147-148 °C. IR 3328, 2943, 2823, 1635, 1539, 1500, 1450, 1300, 1242, 1026, 752 cm⁻¹. ¹H NMR (360 MHz, CDCl₃) δ 1.80 (m, 4 H), 2.61 (br t, 4 H, J=6.58 Hz), 2.76 (m, 8 H), 3.17 (m, 8 H), 3.28 (dt, 4 H, J₁ = 5.98 Hz, J₂ = 5.85 Hz), 3.86 (s, 6 H), 4.25 (m, 4 H), 4.31 (m, 4 H), 4.55 (m, 4H), 4.61 (m, 4 H), 5.57 (s, 4 H), 6.84-6.89 (m, 2 H), 6.90-6.96 (m, 4 H), 6.98-7.04 (m, 2 H), 7.36-7.42 (m, 4 H), 7.51–7.62 (m, 8 H). ¹³C NMR (90 MHz, CDCl₃) δ 25.28, 39.15, 50.44, 50.54, 53.79, 55.41, 57.43, 68.59, 69.78,

69.97, 70.88, 76.86, 78.73, 111.33, 118.26, 120.17, 121.07, 123.09, 127.77, 128.66, 134.11, 140.73, 141.12, 145.54, 152.33, 169.10. HPLC system A (245 nm) purity 95% ($t_R = 16.7$ min); system D (245 nm) purity 98% ($t_R = 17.4$ min). APCI-MS calcd m/z for C₆₈H₇₄Fe₂N₁₂O₄: 1235.1 found 1236 (M + H)⁺.

1',1"-[Biphenyl-4,4'-diylbis(methylene-1H-1,2,3-triazole-1,4diyl)]bis(N-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}ferrocene-1-carboxamide) (14b). Compound 14b was prepared according to the protocol of 14a using a suspension of 9b (39 mg, 78 μmol), 4,4'-bis(azidomethyl)biphenyl (6.9 mg, 26 μmol), sodium ascorbate (1.0 mg, 5.0 µmol), and copper sulfate pentahydrate (0.3 mg, 1.2 μ mol) in H₂O (2 mL), ^tBuOH (1 mL), and CH₂Cl₂(1 mL) to give **14b** as an orange solid (32 mg, 96% yield); mp 147-150 °C. IR 3402, 2939, 2819, 1631, 1539, 1500, 1450, $1300, 1242, 1026, 752 \text{ cm}^{-1}$. ¹H NMR (360 MHz, CDCl₃) δ 1.61–1.76 (m, 8 H), 2.53 (m, 4 H), 2.73 (m, 8 H), 3.13 (m, 8 H), 3.32 (m, 4 H), 3.84 (s, 6 H), 4.26 (m, 4 H), 4.33 (m, 4 H), 4.47 (m, 4 H), 4.55 (m, 4 H), 5.58 (s, 4 H), 6.81-7.04 (m, 8 H), 7.11 (m, 2 H), 7.34–7.44 (m, 4 H), 7.49 (s, 2 H), 7.55–7.67 (m, 4 H). ³C NMR (150 MHz, CDCl₃,) δ 24.07, 27.57, 39.30, 50.29, 53.34, 53.83, 55.37, 58.17, 69.12, 69.83, 70.40, 70.74, 76.44, 78.72, 111.23, 118.29, 120.09, 121.02, 123.05, 127.80, 128.64, 134.02, 140.72, 141.12, 145.98, 152.27, 169.71. HPLC system C (245 nm) purity 95% ($t_{\rm R}$ = 18.0 min); system D (245 nm) purity 97% ($t_{\rm R}$ = 17.1 min). APCI-MS calcd m/z for C₇₀H₇₈Fe₂N₁₂O₄: 1263.1, found 1264 $(M + H)^+$

1',1"-[Decane-1,10-diylbis(1H-1,2,3-triazole-1,4-diyl)]bis-(N-{3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}ferrocene-1carboxamide) (14c). Compound 14c was prepared according to the protocol of 14a using a suspension of 9a (38 mg, 78 µmol), 1,10-diazidodecane (5.9 mg, 26 µmol), sodium ascorbate (1.0 mg, 5.0 μ mol), and copper sulfate pentahydrate (0.3 mg, 1.2 µmol) in H₂O (2 mL), ^tBuOH (1 mL), and CH₂Cl₂ (1 mL). Purification by flash chromatography (CH₂Cl₂:MeOH 98:2-9:1) gave 14c as an orange-brown solid (21 mg, 69% yield); mp 61–62 °C. IR 3313, 2931, 2819, 1635, 1539, 1500, 1454, 1242, 1026, 910, 733 cm⁻¹. ¹H NMR (360 MHz, CDCl₃) δ 1.20-1.41 (m, 12 H), 1.82 (m, 4 H), 1.92 (m, 4 H), 2.61 (br t, 4 H, J=6.47 Hz), 2.76 (m, 8 H), 3.17 (m, 8 H), 3.32 (dt, 4 H, J₁=6.06 Hz, $J_2 = 5.96 Hz$), 3.86 (s, 6 H), 4.26 (m, 4 H), 4.30 - 4.37 (m, 8 H), 4.53 (m, 4 H), 4.63 (m, 4 H), 6.84-6.89 (m, 2 H), 6.90-6.98 (m, 4 H), 6.99–7.05 (m, 2 H), 7.55 (s, 2 H), 7.58 (m, 2 H). ¹³C NMR (150 MHz, CDCl₃) δ 25.30, 26.50, 28.93, 29.23, 30.26, 39.17, 50.34, 50.46, 53.53, 55.40, 57.45, 68.63, 69.72, 70.01, 70.85, 77.09, 78.67, 111.25, 118.23, 119.99, 121.04, 123.06, 141.11, 144.95, 152.30, 169.19. HPLC system C (245 nm) purity 96% $(t_{\rm R} = 18.7 \text{ min})$. APCI-MS calcd m/z for C₆₄H₈₂Fe₂N₁₂O₄: 1195.1, found 1196 $(M + H)^+$.

1',1"-[Decane-1,10-diylbis(1*H*-1,2,3-triazole-1,4-diyl)]bis-(N-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}ferrocene-1carboxamide) (14d). Compound 14d was prepared according to the protocol of 14a using a suspension of 9b (39 mg, 78 µmol), 1,10-diazidodecane (5.9 mg, 26 µmol), sodium ascorbate (1.0 mg, 5.0 μ mol), and copper sulfate pentahydrate (0.3 mg, 1.2 µmol) in H₂O (2 mL), ^tBuOH (1 mL), and CH₂Cl₂ (1 mL). Purification by flash chromatography (CH₂Cl₂:MeOH 98:2-9:1) gave 14d as an orange solid (20 mg, 61% yield); mp 63-64 °C. IR 3332, 2931, 2819, 1635, 1539, 1500, 1454, 1242, 1026, 752 cm^{-1} . ¹H NMR (600 MHz, CDCl₃) δ 1.18–1.39 (m, 12 H), 1.63-1.73 (m, 8 H), 1.92 (m, 4 H), 2.52 (m, 4 H), 2.73 (m, 8 H), 3.13 (m, 8 H), 3.33 (m, 4 H), 3.85 (s, 6 H), 4.27 (m, 4 H), 4.30-4.37 (m, 8 H), 4.45 (m, 4 H), 4.57 (m, 4 H), 6.83-6.87 (m, 2 H), 6.89-6.96 (m, 4 H), 6.97-7.02 (m, 2 H), 7.16 (m, 2 H), 7.51 (s, 2 H). ¹³C NMR (150 MHz, CDCl₃) δ 24.15, 26.50, 27.62, 28.94, 29.24, 30.27, 39.36, 50.36, 50.39, 53.38, 55.38, 58.22, 69.15, 69.77, 70.43, 70.71, 76.68, 78.71, 111.22, 118.27, 119.92, 121.02, 123.01, 141.17, 145.38, 152.27, 169.75. HPLC system A (245 nm) purity 96% ($t_{\rm R}$ = 17.2 min); system D (245 nm) purity 96% ($t_{\rm R} = 17.7$ min). APCI-MS calcd m/z for C₆₆H₈₆Fe₂N₁₂O₄: 1223.2 found 1224 $(M + H)^+$.

1,1"-[Dodecane-1,12-diylbis(1H-1,2,3-triazole-1,4-diyl)]bis-(N-{3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}ferrocene-1carboxamide) (14e). Compound 14e was prepared according to the protocol of 14a using a suspension of 9a (58 mg, 0.12 mmol), 1,12-diazidododecane (9.9 mg, 39 μ mol), sodium ascorbate (1.5 mg, 7.8 μ mol), and copper sulfate pentahydrate (0.5 mg, 2.0 μ mol) in H₂O (2 mL), ^tBuOH (1 mL), and CH₂Cl₂ (1 mL) to give 14e as an orange solid (42 mg, 87% yield); mp 116-118 °C. IR 3332, 2927, 1635, 1539, 1500, 1454, 1242, 1026, 752 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 1.21-1.40 (m, 16 H), 1.81 (m, 4 H), 1.92 (m, 4 H), 2.59 (br t, 4 H, J=6.42 Hz), 2.74 (m, 8 H), 3.16 (m, 8 H), 3.32 (dt, 4 H, $J_1 = 5.92$ Hz, $J_2 = 5.76$ Hz), 3.87 (s, 6 H), 4.26 (m, 4 H), 4.30–4.36 (m, 8 H), 4.53 (m, 4 H), 4.62 (m, 4 H), 6.85–6.90 (m, 2 H), 6.92-6.97 (m, 4 H), 6.99-7.04 (m, 2 H), 7.55 (s, 2 H), 7.59 (m, 2 H). ¹³C NMR (150 MHz, CDCl₃) δ 25.37, 26.53, 28.99, 29.35, 29.41, 30.28, 39.25, 50.36, 50.56, 53.56, 55.38, 57.51, 68.63, 69.70, 70.01, 70.82, 77.09, 78.71, 111.24, 118.20, 119.98, 121.03, 123.02, 141.19, 144.93, 152.30, 169.17. HPLC system D (245 nm) purity >99% ($t_{\rm R}$ = 19.2 min). APCI-MS calcd m/z for C₆₆H₈₆- $Fe_2N_{12}O_4$: 1223.2 found 1224 (M + H)⁺

1,1"-[Dodecane-1,12-diylbis(1H-1,2,3-triazole-1,4-diyl)]bis-(N-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}ferrocene-1carboxamide) (14f). Compound 14f was prepared according to the protocol of 14a using a suspension of 9b (72.4 mg, 145 µmol), 1,12-diazidododecane (12.2 mg, 48.3 µmol), sodium ascorbate (1.90 mg, 9.60 μ mol), and copper sulfate pentahydrate (0.6 mg, $2.40 \,\mu\text{mol}$) in H₂O (2 mL), ^tBuOH (1 mL), and CH₂Cl₂ (1 mL) to give 14f as an orange solid (59.9 mg, 99% yield); mp 141-143 °C. IR 3317, 2931, 1635, 1539, 1500, 1454, 1300, 1242, 1026, 752 cm⁻¹. ¹H NMR (360 MHz, CDCl₃) δ 1.17-1.45 (m, 16 H), 1.60-1.78 (m, 8 H), 1.92 (m, 4 H), 2.51 (m, 4 H), 2.70 (m, 8 H), 3.12 (m, 8 H), 3.34 (m, 4 H), 3.85 (s, 6 H), 4.27 (m, 4 H), 4.30–4.39 (m, 8 H), 4.45 (m, 4 H), 4.57 (m, 4 H), 6.82–7.03 (m, 8 H), 7.14 (m, 2 H), 7.51 (s, 2 H). 13 C NMR (150 MHz, CDCl₃) δ 24.25, 26.54, 27.66, 29.00, 29.37, 29.43, 30.29, 39.40, 50.43, 53.40, 55.37, 58.26, 69.17, 69.76, 70.45, 70.69, 76.69, 78.73, 111.21, 118.25, 119.91, 121.00, 122.97, 141.24, 145.38, 152.28, 169.75. HPLC system D (245 nm) purity 99% ($t_{\rm R} = 19.1$ min). APCI-MS calcd *m*/*z* for C₆₈H₉₀Fe₂N₁₂O₄: 1251.2, found 1252 $(M + H)^{+}$

1,1"-[Biphenyl-4,4'-diylbis(methylene-1H-1,2,3-triazole-1,4diyl)]diferrocene-1-carbaldehyde (15a). A suspension of 1'-ethynylferrocene-1-carbaldehyde (11, 58.3 mg, 245 µmol), 4,4'-bis-(azidomethyl)biphenyl (21.6 mg, 81.7 µmol), sodium ascorbate $(3.20 \text{ mg}, 16.2 \mu \text{mol})$, and copper sulfate pentahydrate (1.0 mg, 1.0 mg)4.00 µmol) in H₂O (4 mL), ^tBuOH (2 mL), and CH₂Cl₂ (2 mL) was stirred at room temperature overnight. Afterward, the reaction was quenched with saturated aqueous NaHCO₃ and extracted with CH2Cl2. The combined organic layers were dried (Na₂SO₄) and the solvent was removed under reduced pressure. The residue was purified by flash chromatography (CH₂Cl₂: MeOH 98:2) to give 15a as a brown solid (60.2 mg, 99% yield); $mp > 200 \circ C$ (decomposition). IR 3120, 1678, 1454, 1246, 1045, 1 822, 760 cm⁻¹. ¹H NMR (360 MHz, C₆D₆/CD₃CN) δ 4.20 (m, 4 H), 4.30 (m, 4 H), 4.56 (m, 4H), 4.77 (m, 4 H), 5.37 (s, 4 H), 7.26-7.32 (m, 4 H), 7.43-7.54 (m, 6 H), 9.69 (s, 2 H). ¹³C NMR (90 MHz, C₆D₆/CD₃CN) δ 53.35, 68.11, 70.10, 70.96, 74.45, 78.51, 80.72, 120.47, 135.32, 140.52, 144.99, 150.90, 170.47, 192.99. APCI-MS calcd m/z for C₄₀H₃₂Fe₂N₆O₂: 740.4, found $741 (M + H)^+$.

1,1"-[Decane-1,10-diylbis(1*H*-1,2,3-triazole-1,4-diyl)]diferrocene-1-carbaldehyde (15b). Compound 15b was prepared according to the protocol of 15a using a suspension of 11 (45.2 mg, 190 μ mol), 1,10-diazidodecane (14.2 mg, 63.3 μ mol), sodium ascorbate (2.50 mg, 12.6 μ mol), and copper sulfate pentahydrate (0.8 mg, 3.20 μ mol) in H₂O (2 mL), 'BuOH (1 mL), and CH₂Cl₂ (1 mL) to give 15b as an orange-brown solid (43.5 mg, 98% yield); mp 153-156 °C. IR 3116, 2924, 2854 1678, 1454, 1246, 1038, 822, 744 cm⁻¹. ¹H NMR (360 MHz, CDCl₃) δ 1.20-1.42 (m, 12 H), 1.93 (m, 4 H), 4.35 (t, 4 H *J*=7.27 Hz), 4.38 (m, 4 H), 4.53 (m, 4 H), 4.66 (m, 4 H), 4.82 (m, 4 H), 7.46 (s, 2 H), 9.70 (s, 2 H). 13 C NMR (150 MHz, CDCl₃) δ 26.40, 28.86, 29.17, 30.19, 50.34, 67.98, 69.95, 70.97, 74.45, 77.93, 79.95, 119.42, 144.45, 193.56. HPLC system A (245 nm) purity 96% ($t_{\rm R}$ = 20.8 min). APCI-MS calcd m/z for C₃₆H₄₀Fe₂N₆O₂: 700.4, found 701 (M + H)⁺.

1',1"-[Dodecane-1,12-diylbis(1*H*-1,2,3-triazole-1,4-diyl)]diferrocene-1-carbaldehyde (15c). Compound 15c was prepared according to the protocol of 15a using a suspension of 11 (31.0 mg, 130 μmol), 1,12-diazidododecane (10.9 mg, 43.2 μmol), sodium ascorbate (1.70 mg, 8.58 μmol), and copper sulfate pentahydrate (0.6 mg, 2.40 μmol) in H₂O (2 mL), 'BuOH (1 mL), and CH₂Cl₂(1 mL) to give 15c as an orange solid (30.0 mg, 95% yield); mp 112–114 °C. IR 3116, 2927, 2854 1678, 1454, 1242, 1045, 825, 744 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 1.20–1.40 (m, 16 H), 1.93 (m, 4 H), 4.35 (t, 4 H, *J*=7.37 Hz), 4.38 (m, 4 H), 4.53 (m, 4 H), 4.67 (m, 4 H), 4.83 (m, 4 H), 7.47 (s, 2 H), 9.71 (s, 2 H). ¹³C NMR (90 MHz, CDCl₃) δ 26.46, 28.94, 29.32, 29.37, 30.23, 50.40, 68.02, 69.98, 71.00, 74.48, 77.96, 79.98, 119.43, 144.46, 193.57. APCI-MS calcd *m*/*z* for C₃₈H₄₄Fe₂-N₆O₂: 728.5 found 729 (M + H)⁺.

1,1'-[Biphenyl-4,4'-diylbis(methylene-1H-1,2,3-triazole-1,4diylferrocene-1,1'-diylmethylene)]bis[4-(2-methoxyphenyl)piperazine] (16a). A solution of 15a (20 mg, 27 µmol), 1-(2-methoxyphenyl)piperazine (16 mg, 83 µmol), and Na(OAc)₃BH (24 mg, 0.11 mmol) in anhydrous CH2Cl2 (6 mL) was stirred at room temperature overnight. The reaction mixture was quenched with saturated aqueous NaHCO₃ and extracted with CH₂Cl₂. The combined organic layers were dried (Na₂SO₄) and evaporated. The residue was purified by flash chromatography (CH₂Cl₂: MeOH 98:2-95:5) to give 16a as an orange solid (21.9 mg, 74%) yield); mp 238-240 °C (decomposition). IR 2925, 1591, 1498, 1450, 1240, 1024, 910, 802, 733, 663 cm⁻¹. ¹H NMR (360 MHz, $CDCl_3 + 0.5\%$ HCOOH) δ 2.80 (m, 4 H), 3.05 (m, 4 H), 3.18-3.41 (m, 8 H), 3.64 (s, 4 H), 3.80 (s, 6 H), 4.23 (m, 8 H), 4.32 (m, 4 H), 4.73 (m, 4 H), 5.60 (s, 4 H), 6.75-6.96 (m, 6 H), 6.99-7.09 (m, 2 H), 7.37-7.47 (m, 4 H), 7.51-7.66 (m, 6 H). ¹³C NMR (150 MHz, CDCl₃) δ (ppm): 49.28, 51.72, 53.77, 55.34, 56.71, 67.16, 69.35, 70.18, 72.14, 76.02, 79.77, 111.18, 118.37, 119.07, 121.01, 123.32, 127.76, 128.62, 134.33, 140.55, 140.58, 146.39, 152.15. HPLC system A (245 nm) purity 95% ($t_{\rm R} = 16.4$ min). APCI-MS calcd m/z for C₆₂H₆₄Fe₂N₁₀O₂: 1092.9, found $1094 (M + H)^+$

1,1'-[Decane-1,10-diylbis(1H-1,2,3-triazole-1,4-diylferrocene-**1,1'-diylmethylene**)]bis[4-(2-methoxyphenyl)piperazine] (16b). Compound 16b was prepared according to the protocol of 16a using a solution of 15b (20.3 mg, 29.0 µmol), 1-(2-methoxyphenyl)piperazine (16.7 mg, 87.0 µmol), and Na(OAc)₃BH (25.7 mg, 116 µmol) in CH₂Cl₂ (7 mL). Purification by flash chromatography (CH₂Cl₂:MeOH 98:2) gave 16b as an orange-brown solid (14.8 mg, 48% yield); mp 148-151 °C. IR 2931, 2819, 1500, 1454, 1238, 1026, 748 cm⁻¹. ¹H NMR (360 MHz, CDCl₃) δ 1.20-1.41 (m, 12 H), 1.91 (m, 4 H), 2.56 (m, 8 H), 3.03 (m, 8 H), 3.24 (s, 4 H), 3.82 (s, 6 H), 4.05 (m, 4 H), 4.10 (m, 4 H), 4.27 (m, 4 H), 4.33 (t, 4 H, J = 7.27 Hz), 4.68 (m, 4 H), 6.80–6.85 (m, 2 H), 6.86–6.92 (m, 4 H), 6.93–7.01 (m, 2 H), 7.45 (s, 2 H). ¹³C NMR (150 MHz, CDCl₃) δ 26.47, 28.91, 29.23, 30.33, 50.26, 50.31, 52.68, 55.33, 57.61, 66.99, 69.17, 69.76, 71.82, 76.02, 82.70, 111.15, 118.21, 118.62, 120.97, 122.89, 141.25, 146.07, 152.23. HPLC system A (245 nm) purity 96% ($t_{\rm R}$ = 17.0 min). APCI-MS calcd m/z for C₅₈H₇₂Fe₂N₁₀O₂: 1053.0, found 1054 (M + H)⁺.

1,1'-[Dodecane-1,12-diylbis(1*H*-1,2,3-triazole-1,4-diylferrocene-1,1'-diylmethylene)]bis[4-(2-methoxyphenyl)piperazine] (16c). Compound 16c was prepared according to the protocol of 16a using a solution of 15c (23.4 mg, 32.1 μmol), 1-(2-methoxyphenyl)piperazine (18.5 mg, 96.3 μmol), and Na(OAc)₃BH (28.4 mg, 128 μmol) in CH₂Cl₂ (7 mL) to give 16c as a yellow-orange oil (29.4 mg, 84% yield). IR 2927, 2854, 1593, 1500, 1454, 1242, 1026, 752 cm⁻¹. ¹H NMR (360 MHz, CDCl₃ + 0.5% HCOOH) δ 1.18–1.40 (m, 16 H), 1.93 (m, 4 H), 3.03 (m, 8 H), 3.22 (m, 8 H), 3.67 (s, 4 H), 3.82 (s, 6 H), 4.20 (m, 4 H), 4.24 (m, 4 H), 4.32 (m, 4 H), 4.33 (t, 4 H, J = 7.38 Hz), 4.75 (m, 4 H), 6.81–6.96 (m, 6 H), 6.98–7.06 (m, 2 H), 7.59 (s, 2 H). ¹³C NMR (150 MHz, CDCl₃ + 0.5% HCOOH) δ 26.51, 28.98, 29.36, 29.42, 30.32, 47.81, 50.42, 50.56, 55.40, 55.66, 67.34, 69.51, 70.97, 72.47, 75.32, 76.76, 111.24, 118.66, 119.52, 121.14, 124.03, 139.43, 145.07, 152.03. HPLC system A (245 nm) purity 97% ($t_{\rm R}$ =17.8 min). APCI-MS calcd m/z for C₆₀H₇₆Fe₂N₁₀O₂: 1081.0, found 1082 (M + H)⁺.

Dopamine Receptor Binding Studies. Receptor binding studies were carried out as described.³¹ In brief, the dopamine D1 receptor assay was done with porcine striatal membranes at a final protein concentration of 40 μ g/assay tube and the radioligand [³H]SCH 23390 at 0.3 nM ($K_d = 0.41-0.58$ nM). Competition experiments with human D2_{long}, D2_{short},²⁸ D3,²⁹ and D4.4³⁰ receptors were run with preparations of membranes from CHO cells stably expressing the corresponding receptor and [³H]spiperone at a final concentration of 0.1–0.2 nM. The assays were carried out at a protein concentration of 5–20 μ g/assay tube and K_d values of 0.07–0.15, 0.05–0.13, 0.11–0.19, and 0.17–0.35 nM for the D2_{long}, D2_{short}, D3, and D4.4 receptors, respectively. Protein concentration was established by the method of Lowry using bovine serum albumin as standard.³⁷

Data Analysis. The resulting competition curves of the receptor binding experiments were analyzed by nonlinear regression using the algorithms in PRISM 3.0 (GraphPad Software, San Diego, CA). The data were initially fit using a sigmoid model to provide an IC₅₀ value, representing the concentration corresponding to 50% of maximal inhibition. IC₅₀ values were transformed to K_i values according to the equation of Cheng and Prusoff.³⁸ In the fact of two individual measurements K_i was calculated as mean value in nM with the standard deviation (SD), while analyzing more than two single values the standard error of mean (SEM) was calculated as manner of confidence.

Mitogenesis Experiments. Determination of the intrinsic activity of the representative compound was carried out by measuring the incorporation of [³H]thymidine into growing cells after stimulation with the test compound as described in the literature.^{4,36} For this assay, D3 expressing CHO dhfr⁻ cells as well as D2_{long} and D4.2 expressing CHO100001 cells have been incubated with 0.02 μ Ci [³H]thymidine per well (specific activity 25 μ Ci/mmol). Dose–response curves of 6–10 experiments have been normalized and pooled to get a mean curve from which the EC₅₀ value and the maximum intrinsic activity of each compound could be compared to the effects of the full agonist quinpirole.

Acknowledgment. This work was supported by the Deutsche Forschungsgemeinschaft (DFG: Gm 13/8).

Supporting Information Available: Synthesis of compounds 17–20, analytical data (¹H NMR, ¹³C NMR, LC-MS, or HPLC spectra), receptor binding data employing porcine 5-HT_{1A}, 5-HT₂, and α_1 receptors of all target compounds and further mitogenesis experiments with 10b at D2_{long}, and reference agents. This material is available free of charge via the Internet at http://pubs.acs.org.

References

- (1) Chen, X.; Wang, W. The use of bioisosteric groups in lead optimization. *Annu. Rep. Med. Chem.* **2003**, *38*, 333–346.
- (2) Biot, C.; Glorian, G.; Maciejewski, L. A.; Brocard, J. S. Synthesis and Antimalarial Activity in Vitro and in Vivo of a New Ferrocene-Chloroquine Analogue. J. Med. Chem. 1997, 40, 3715–3718.
- (3) Dubar, F.; Khalife, J.; Brocard, J.; Dive, D.; Biot, C. Ferroquine, an Ingenious Antimalarial Drug—Thoughts on the Mechanism of Action. *Molecules* 2008, 13, 2900–2907.
- (4) Bettinetti, L.; Schlotter, K.; Hubner, H.; Gmeiner, P. Interactive SAR Studies: Rational Discovery of Super-Potent and Highly

Selective Dopamine D3 Receptor Antagonists and Partial Agonists. J. Med. Chem. 2002, 45, 4594–4597.

- (5) Newman, A. H.; Grundt, P.; Nader, M. A. Dopamine D3 Receptor Partial Agonists and Antagonists as Potential Drug Abuse Therapeutic Agents. J. Med. Chem. 2005, 48, 3663–3679.
- (6) Schlotter, K.; Boeckler, F.; Hubner, H.; Gmeiner, P. Fancy Bioisosters: Metallocene-Derived G-Protein-Coupled Receptor Ligands with Subnanomolar Binding Affinity and Novel Selectivity Profiles. J. Med. Chem. 2005, 48, 3696–3699.
- (7) Boeckler, F.; Gmeiner, P. Dopamine D3 receptor ligands—recent advances in the control of subtype selectivity and intrinsic activity. *Biochim. Biophys. Acta* 2007, 1768, 871–887.
- (8) Leopoldo, M.; Berardi, F.; Colabufo, N. A.; De Giorgio, P.; Lacivita, E.; Perrone, R.; Tortorella, V. Structure–Affinity Relationship Study on N-[4-(4-Arylpiperazin-1-yl)butyl]arylcarboxamides as Potent and Selective Dopamine D3 Receptor Ligands. J. Med. Chem. 2002, 45, 5727–5735.
- (9) Hackling, A.; Ghosh, R.; Perachon, S.; Mann, A.; Holtje, H.-D.; Wermuth, C. G.; Schwartz, J.-C.; Sippl, W.; Sokoloff, P.; Stark, H. *N*-(ω-(4-(2-Methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as Dopamine D2 and D3 Receptor Ligands. *J. Med. Chem.* 2003, 46, 3883–3899.
- (10) Murray, P. J.; Harrison, L. A.; Johnson, M. R.; Robertson, G. M.; Scopes, D. I. C.; Bull, D. R.; Graham, E. A.; Hayes, A. G.; Kilpatrick, G. J.; Daas, I. D.; Large, C.; Sheehan, M. J.; Stubbs, C. M.; Turpin, M. P. A novel series of arylpiperazines with high affinity and selectivity for the dopamine D3 receptor. *Biorg. Med. Chem. Lett.* **1995**, *5*, 219–222.
- (11) Boeckler, F.; Gmeiner, P. The Structural Evolution of Dopamine D3 Receptor Ligands—Structure–Activity Relationships and Selected Neuropharmacological Aspects. *Pharmacol. Ther.* 2006, *112*, 281–333.
- (12) Ehrlich, K.; Gotz, A.; Bollinger, S.; Tschammer, N.; Bettinetti, L.; Harterich, S.; Hubner, H.; Lanig, H.; Gmeiner, P. Dopamine D2, D3, and D4 Selective Phenylpiperazines as Molecular Probes To Explore the Origins of Subtype Specific Receptor Binding. *J. Med. Chem.* **2009**, *52*, 4923–4935.
- (13) Badèche, S.; Daran, J.-C.; Ruiz, J.; Astruc, D. Synthesis and Coordination Chemistry of Ferrocenyl-1,2,3-triazolyl Ligands. *Inorg. Chem.* 2008, 47, 4903–4908.
- (14) Koster, S. D.; Dittrich, J.; Gasser, G.; Husken, N.; Henao Castañeda, I. C.; Jios, J. L.; Della Védova, C. O.; Metzler-Nolte, N. Spectroscopic and Electrochemical Studies of Ferrocenyl Triazole Amino Acid and Peptide Bioconjugates Synthesized by Click Chemistry. Organometallics 2008, 27, 6326–6332.
- (15) Siemeling, U.; Rother, D. Evaluation of heterocumulenic ferrocene derivatives for "click" chemistry type reactions. J. Organomet. Chem. 2009, 694, 1055–1058.
- (16) Schottenberger, H.; Lukassser, J.; Reichel, E.; Muller, A. G.; Steiner, G.; Kopacka, H.; Wurst, K.; Ongania, K. H.; Kirchner, K. Semimasked 1,1'-diethynylferrocenes: synthetic concepts, preparations and reactions. J. Organomet. Chem. 2001, 637–639, 558– 576.
- (17) Barišić, L.; Rapić, C.; Pritzkow, H.; Pavlović, G.; Nemet, I. Ferrocene compounds. Part XXXIII. Synthesis and characterization of amino acids containing skeletal 1,1'-ferrocenylene unit. J. Organomet. Chem. 2003, 682, 131–142.
- (18) Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective "Ligation" of Azides and Terminal Alkynes. *Angew. Chem., Int. Ed.* 2002, *41*, 2596–2599.
- (19) Alvarez, S. G.; Alvarez, M. T. A Practical Procedure for the Synthesis of Alkyl Azides at Ambient Temperature in Dimethyl Sulfoxide in High Purity and Yield. *Synthesis* 1997, 413.
- (20) Lieber, E.; Chao, T. S.; Ramachandra Rao, C. N. Improved Method for the Synthesis of Alkyl Azides. J. Org. Chem. 1957, 22, 238–240.
- (21) Lober, S.; Hubner, H.; Utz, W.; Gmeiner, P. Rationally Based Efficacy Tuning of Selective Dopamine D4 Receptor Ligands Leading to the Complete Antagonist 2-[4-(4-Chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 213). J. Med. Chem. 2001, 44, 2691–2694.
- (22) Tietze, R.; Lober, S.; Hubner, H.; Gmeiner, P.; Kuwerta, T.; Prante, O. Discovery of a dopamine D4 selective PET ligand candidate taking advantage of a click chemistry based REM linker. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 983–988.
- (23) Enguehard-Gueiffier, C.; Hubner, H.; El Hakmaoui, A.; Allouchi, H.; Gmeiner, P.; Argiolas, A.; Melis, M. R.; Gueiffier, A. 2-[(4-Phenylpiperazin-1-yl)methyl]imidazo(di)azines as Selective D4-Ligands. Induction of Penile Erection by 2-[4-(2-Methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-*a*]pyridine (PIP3EA), a Potent and Selective D4 Partial Agonist. J. Med. Chem. 2006, 49, 3938–3947.

- (24) Weiss, S.; Keller, M.; Bernhardt, G.; Buschauer, A.; Konig, B. Modular synthesis of non-peptidic bivalent NPY Y1 receptor antagonists. *Bioorg. Med. Chem.* 2008, *16*, 9858–9866.
- (25) Zheng, Y.; Akgun, E.; Harikumar, K. G.; Hopson, J.; Powers, M. D.; Lunzer, M. M.; Miller, L. J.; Portoghese, P. S. Induced Association of μ Opioid (MOP) and Type 2 Cholecystokinin (CCK2) Receptors by Novel Bivalent Ligands. J. Med. Chem. 2009, 52, 247–258.
- (26) Thomas, J. R.; Liu, X.; Hergenrother, P. J. Size-Specific Ligands for RNA Hairpin Loops. J. Am. Chem. Soc. 2005, 127, 12434–12435.
- (27) Wilcox, R. E.; Huang, W. H.; Brusniak, M. Y.; Wilcox, D. M.; Pearlman, R. S.; Teeter, M.; DuRand, C. J.; Wiens, B. L.; Neve, K. A. CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors. J. Med. Chem. 2000, 43, 3005–3019.
- (28) Hayes, G.; Biden, T. J.; Selbie, L. A.; Shine, J. Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2_A and D2_B subtypes in a heterologous cell line. *Mol. Endocrinol.* **1992**, *6*, 920–926.
- (29) Sokoloff, P.; Andrieux, M.; Besançon, R.; Pilon, C.; Martres, M.-P.; Giros, B.; Schwartz, J.-C. Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. *Eur. J. Pharmacol.* **1992**, *225*, 331–337.
- (30) Asghari, V.; Sanyal, S.; Buchwaldt, S.; Paterson, A.; Jovanovic, V.; Van Tol, H. H. M. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. *J. Neurochem.* **1995**, 65, 1157–1165.
- (31) Hubner, H.; Haubmann, C.; Utz, W.; Gmeiner, P. Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding

experiments, and computational studies of novel dopamine receptor agonists recognizing preferentially the D3 subtype. *J. Med. Chem.* **2000**, *43*, 756–762.

- (32) Pilla, M.; Perachon, S.; Sautel, F.; Garrido, F.; Mann, A.; Wermuth, C. G.; Schwartz, J.-C.; Everitt, B. J.; Sokoloff, P. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. *Nature* **1999**, *400*, 371–375.
- (33) George, S. R.; O'Dowd, B. F.; Lee, S. P. G-protein-coupled receptor oligomerization and its potential for drug discovery. *Nat. Rev. Drug Discovery* 2002, *1*, 808–820.
- (34) Han, Y.; Moreira, I. S.; Urizar, E.; Weinstein, H.; Javitch, J. A. Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. *Nat. Chem. Biol.* 2009, *5*, 688– 695.
- (35) Mierau, J.; Schneider, F. J.; Ensinger, H. A.; Chio, C. L.; Lajiness, M. E.; Huff, R. M. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. *Eur. J. Pharmacol.* **1995**, *290*, 29–36.
- (36) Hubner, H.; Kraxner, J.; Gmeiner, P. Cyanoindole derivatives as highly selective dopamine D4 receptor partial agonists: solid-phase synthesis, binding assays, and functional experiments. *J. Med. Chem.* 2000, 43, 4563–4569.
- (37) Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* **1951**, *193*, 265–275.
- (38) Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction. *Biochem. Pharmacol.* **1973**, 22, 3099–3108.